Brief: Arcutis Biotherapeutics Says New Data Shows ZORYVE Cream 0.3% Provided Measurable Improvement Of Plaque Psoriasis
20/10/2023 13:22
Oct 20 (Reuters) - Arcutis Biotherapeutics Inc ARQT.O :
* ARCUTIS BIOTHERAPEUTICS : DATA SHOWS ZORYVE® CREAM 0.3%
PROVIDED
MEASURABLE IMPROVEMENT OF PLAQUE PSORIASIS IN NEARLY ALL
INDIVIDUALS IN DERMIS TRIALS
* ARCUTIS BIOTHERAPEUTICS INC: OVER 85% ACHIEVED MEASURABLE
IMPROVEMENT BY WEEK 2 ( EARLIEST TIMEPOINT MEASURED) IN STUDY
* ARCUTIS : SEPARATELY REPORTED NEW DATA CONFIRMS ZORYVE IS
WELL
TOLERATED ACCORDING TO BOTH INVESTIGATOR AND PATIENT LOCAL
TOLERABILITY ASSESSMENTS
Source text for Eikon: ID:nGNX1wWFjp
Further company coverage: ARQT.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Arcutis Biotherapeutics
See all newsBrief: Arcutis Biotherapeutics reports inducement grants under Nasdaq listing rule 5635(C)(4
Arcutis Q1 product revenue rises 65% yr/yr, net loss narrows
Brief: Arcutis Announces Promotion Of MAS Matsuda To Executive Vice President And Chief Legal Officer To Support Next Phase Of Growth
Brief: Arcutis Begins Enrolling Phase 1A/1B Study Evaluating Arq-234, A Cd200r Agonist, In Healthy Volunteers And Adults With Atopic Dermatitis
Brief: Arcutis Biotherapeutics Inc Files For Mixed Shelf